Austin Gerard Smith
British stem cell biologist (born 1960)
From Wikipedia, the free encyclopedia
Austin Gerard Smith (born 1960) is a professor at the University of Exeter and director of its Living Systems Institute.[3] He is notable for his pioneering work on the biology of embryonic stem cells.[4][5]
1960 (age 65–66)
Austin Smith | |
|---|---|
| Born | Austin Gerard Smith 1960 (age 65–66) Merseyside, UK[1] |
| Alma mater | University of Edinburgh |
| Awards | Louis-Jeantet Prize for Medicine (2010) [2] |
| Scientific career | |
| Fields | Stem Cells |
| Institutions | University of Exeter |
| Thesis | (1986) |
| Doctoral advisor | Martin Hooper[citation needed] |
| Website | www.exeter.ac.uk[3] |
Education
Austin Smith obtained his doctoral degree from the University of Edinburgh in 1986.[6][7]
Career and research
He then carried out postdoctoral research at the University of Oxford, before joining the Centre for Genome Research at the University of Edinburgh as a group leader.[6] In 1996, he was appointed director of the centre, which became the Institute for Stem Cell Research under his leadership.[6] He remained as director of the Institute until his move to Cambridge in 2006.[8] Here, he became a director of the Welcome Trust Centre for Stem Cell Research [9] and later was the director of the new Wellcome Trust-MRC Cambridge Stem Cell Institute at the University of Cambridge, which was established with 8 million pounds ($12.5 million) awarded by the Wellcome Trust and Medical Research Council (UK) in 2012.[10]
In 2019, he was appointed as the new Director of the University of Exeter's Living Systems Institute.[3]
In 2003, Smith was awarded an MRC Research Professorship[6] and elected to the Royal Society of Edinburgh.[11] And in 2006, was elected a Fellow of the Royal Society.[12] In 2010, he was co-recipient of the Louis-Jeantet Prize for Medicine along with French cardiologist Michel Haissaguerre.[2]
In February 2010, together with 13 other leading stem cell researchers, he wrote an open letter to journal editors to voice the opinion that obstructive reviews by a small number of researchers in the field were hindering publication of novel stem cell research.[13][14]
